HE is a potentially fatal brain disorder that is caused by liver damage, which results in the failure to remove toxins from the blood.
The availability of patient-focused programs to assist disease management is one of the primary growth drivers for the global hepatic encephalopathy (HE) therapeutics market till 2023. Such programs increase the adherence to therapeutics by improving convenience for patients. Norgine collaborated with the European liver patients association (ELPA) to launch Time to DeLiver program, which is focused on changing the perception about HE among all stakeholders, healthcare professionals, and policymakers. This in turn, drives the demand for diagnosis and management of HE.
The most commonly used therapeutics to treat HE are lactulose and rifaximin. Researchers are also developing treatments that targets ammonia production and removal. For instance, AST-120 is under investigation and targets gut-derived toxins for liver cirrhosis. It can also be used to treat HE. The progression and development of HE sometimes depends on factors such as inflammation. This is compelling researchers to introduce various treatments that targets inflammation. Some of the most recent approaches to treat HE includes probiotics, albumin administration, and
The availability of patient-focused programs to assist disease management is one of the primary growth drivers for the global hepatic encephalopathy (HE) therapeutics market till 2023. Such programs increase the adherence to therapeutics by improving convenience for patients. Norgine collaborated with the European liver patients association (ELPA) to launch Time to DeLiver program, which is focused on changing the perception about HE among all stakeholders, healthcare professionals, and policymakers. This in turn, drives the demand for diagnosis and management of HE.
The most commonly used therapeutics to treat HE are lactulose and rifaximin. Researchers are also developing treatments that targets ammonia production and removal. For instance, AST-120 is under investigation and targets gut-derived toxins for liver cirrhosis. It can also be used to treat HE. The progression and development of HE sometimes depends on factors such as inflammation. This is compelling researchers to introduce various treatments that targets inflammation. Some of the most recent approaches to treat HE includes probiotics, albumin administration, and
Table of Contents
1 Report Overview
1.1 Study Scope
1.2 Major Manufacturers Covered in This Report
1.3 Market Segment by Type
1.3.1 Global Hepatic Encephalopathy (HE) Therapeutics Market Size Growth Rate by Type (2019-2025)
1.3.2 Lactulose
1.3.3 Rifaximin
1.3.4 Neomycin
1.3.5 Probiotics
1.3.6 Thiamine
1.4 Market Segment by Application
1.4.1 Global Hepatic Encephalopathy (HE) Therapeutics Market Share by Application (2019-2025)
1.4.2 Acute Liver Failure
1.4.3 Portal Systemic Bypass Without Liver Disease
1.4.4 Liver Cirrhosis
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Hepatic Encephalopathy (HE) Therapeutics Market Size
2.1.1 Global Hepatic Encephalopathy (HE) Therapeutics Revenue 2014-2025
2.1.2 Global Hepatic Encephalopathy (HE) Therapeutics Sales 2014-2025
2.2 Hepatic Encephalopathy (HE) Therapeutics Growth Rate by Regions
2.2.1 Global Hepatic Encephalopathy (HE) Therapeutics Sales by Regions 2014-2019
2.2.2 Global Hepatic Encephalopathy (HE) Therapeutics Revenue by Regions 2014-2019
2.3 Industry Trends
2.3.1 Market Top Trends
2.3.2 Market Drivers
3 Market Share by Manufacturers
3.1 Hepatic Encephalopathy (HE) Therapeutics Sales by Manufacturers
3.1.1 Hepatic Encephalopathy (HE) Therapeutics Sales by Manufacturers 2014-2019
3.1.2 Hepatic Encephalopathy (HE) Therapeutics Sales Market Share by Manufacturers 2014-2019
3.2 Revenue by Manufacturers
3.2.1 Hepatic Encephalopathy (HE) Therapeutics Revenue by Manufacturers (2014-2019)
3.2.2 Hepatic Encephalopathy (HE) Therapeutics Revenue Share by Manufacturers (2014-2019)
3.2.3 Global Hepatic Encephalopathy (HE) Therapeutics Market Concentration Ratio (CR5 and HHI)
3.3 Hepatic Encephalopathy (HE) Therapeutics Price by Manufacturers
3.4 Key Manufacturers Hepatic Encephalopathy (HE) Therapeutics Plants/Factories Distribution and Area Served
3.5 Date of Key Manufacturers Enter into Hepatic Encephalopathy (HE) Therapeutics Market
3.6 Key Manufacturers Hepatic Encephalopathy (HE) Therapeutics Product Offered
3.7 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Sales and Revenue for Each Type
4.1.1 Lactulose Sales and Revenue (2014-2019)
4.1.2 Rifaximin Sales and Revenue (2014-2019)
4.1.3 Neomycin Sales and Revenue (2014-2019)
4.1.4 Probiotics Sales and Revenue (2014-2019)
4.1.5 Thiamine Sales and Revenue (2014-2019)
4.2 Global Hepatic Encephalopathy (HE) Therapeutics Sales Market Share by Type
4.3 Global Hepatic Encephalopathy (HE) Therapeutics Revenue Market Share by Type
4.4 Hepatic Encephalopathy (HE) Therapeutics Price by Type
5 Market Size by Application
5.1 Overview
5.2 Global Hepatic Encephalopathy (HE) Therapeutics Sales by Application
6 United States
6.1 United States Hepatic Encephalopathy (HE) Therapeutics Breakdown Data by Company
6.2 United States Hepatic Encephalopathy (HE) Therapeutics Breakdown Data by Type
6.3 United States Hepatic Encephalopathy (HE) Therapeutics Breakdown Data by Application
7 European Union
7.1 European Union Hepatic Encephalopathy (HE) Therapeutics Breakdown Data by Company
7.2 European Union Hepatic Encephalopathy (HE) Therapeutics Breakdown Data by Type
7.3 European Union Hepatic Encephalopathy (HE) Therapeutics Breakdown Data by Application
8 China
8.1 China Hepatic Encephalopathy (HE) Therapeutics Breakdown Data by Company
8.2 China Hepatic Encephalopathy (HE) Therapeutics Breakdown Data by Type
8.3 China Hepatic Encephalopathy (HE) Therapeutics Breakdown Data by Application
9 Rest of World
9.1 Rest of World Hepatic Encephalopathy (HE) Therapeutics Breakdown Data by Company
9.2 Rest of World Hepatic Encephalopathy (HE) Therapeutics Breakdown Data by Type
9.3 Rest of World Hepatic Encephalopathy (HE) Therapeutics Breakdown Data by Application
9.4 Rest of World Hepatic Encephalopathy (HE) Therapeutics Breakdown Data by Countries
9.4.1 Rest of World Hepatic Encephalopathy (HE) Therapeutics Sales by Countries
9.4.2 Rest of World Hepatic Encephalopathy (HE) Therapeutics Revenue by Countries
9.4.3 Japan
9.4.4 Korea
9.4.5 India
9.4.6 Southeast Asia
10 Company Profiles
10.1 ASKA Pharmaceutical
10.1.1 ASKA Pharmaceutical Company Details
10.1.2 Company Description and Business Overview
10.1.3 Sales, Revenue and Market Share of Hepatic Encephalopathy (HE) Therapeutics
10.1.4 Hepatic Encephalopathy (HE) Therapeutics Product Introduction
10.1.5 ASKA Pharmaceutical Recent Development
10.2 COSMO PHARMACEUTICALS
10.2.1 COSMO PHARMACEUTICALS Company Details
10.2.2 Company Description and Business Overview
10.2.3 Sales, Revenue and Market Share of Hepatic Encephalopathy (HE) Therapeutics
10.2.4 Hepatic Encephalopathy (HE) Therapeutics Product Introduction
10.2.5 COSMO PHARMACEUTICALS Recent Development
10.3 Mallinckrodt
10.3.1 Mallinckrodt Company Details
10.3.2 Company Description and Business Overview
10.3.3 Sales, Revenue and Market Share of Hepatic Encephalopathy (HE) Therapeutics
10.3.4 Hepatic Encephalopathy (HE) Therapeutics Product Introduction
10.3.5 Mallinckrodt Recent Development
10.4 Valeant
10.4.1 Valeant Company Details
10.4.2 Company Description and Business Overview
10.4.3 Sales, Revenue and Market Share of Hepatic Encephalopathy (HE) Therapeutics
10.4.4 Hepatic Encephalopathy (HE) Therapeutics Product Introduction
10.4.5 Valeant Recent Development
11 Value Chain and Sales Channels Analysis
11.1 Value Chain Analysis
11.2 Sales Channels Analysis
11.2.1 Hepatic Encephalopathy (HE) Therapeutics Sales Channels
11.2.2 Hepatic Encephalopathy (HE) Therapeutics Distributors
11.3 Hepatic Encephalopathy (HE) Therapeutics Customers
12 Market Forecast
12.1 Global Hepatic Encephalopathy (HE) Therapeutics Sales and Revenue Forecast 2019-2025
12.2 Global Hepatic Encephalopathy (HE) Therapeutics Sales Forecast by Type
12.3 Global Hepatic Encephalopathy (HE) Therapeutics Sales Forecast by Application
12.4 Hepatic Encephalopathy (HE) Therapeutics Forecast by Regions
12.4.1 Global Hepatic Encephalopathy (HE) Therapeutics Sales Forecast by Regions 2019-2025
12.4.2 Global Hepatic Encephalopathy (HE) Therapeutics Revenue Forecast by Regions 2019-2025
12.5 United States Market Forecast
12.6 European Union Market Forecast
12.7 China Market Forecast
12.8 Rest of World
12.8.1 Japan
12.8.2 Korea
12.8.3 India
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.1.1 Research Programs/Design
14.1.1.2 Market Size Estimation
14.1.1.3 Market Breakdown and Data Triangulation
14.1.2 Data Source
14.1.2.1 Secondary Sources
14.1.2.2 Primary Sources
14.2 Author Details
14.3 Disclaimer
1 Report Overview
1.1 Study Scope
1.2 Major Manufacturers Covered in This Report
1.3 Market Segment by Type
1.3.1 Global Hepatic Encephalopathy (HE) Therapeutics Market Size Growth Rate by Type (2019-2025)
1.3.2 Lactulose
1.3.3 Rifaximin
1.3.4 Neomycin
1.3.5 Probiotics
1.3.6 Thiamine
1.4 Market Segment by Application
1.4.1 Global Hepatic Encephalopathy (HE) Therapeutics Market Share by Application (2019-2025)
1.4.2 Acute Liver Failure
1.4.3 Portal Systemic Bypass Without Liver Disease
1.4.4 Liver Cirrhosis
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Hepatic Encephalopathy (HE) Therapeutics Market Size
2.1.1 Global Hepatic Encephalopathy (HE) Therapeutics Revenue 2014-2025
2.1.2 Global Hepatic Encephalopathy (HE) Therapeutics Sales 2014-2025
2.2 Hepatic Encephalopathy (HE) Therapeutics Growth Rate by Regions
2.2.1 Global Hepatic Encephalopathy (HE) Therapeutics Sales by Regions 2014-2019
2.2.2 Global Hepatic Encephalopathy (HE) Therapeutics Revenue by Regions 2014-2019
2.3 Industry Trends
2.3.1 Market Top Trends
2.3.2 Market Drivers
3 Market Share by Manufacturers
3.1 Hepatic Encephalopathy (HE) Therapeutics Sales by Manufacturers
3.1.1 Hepatic Encephalopathy (HE) Therapeutics Sales by Manufacturers 2014-2019
3.1.2 Hepatic Encephalopathy (HE) Therapeutics Sales Market Share by Manufacturers 2014-2019
3.2 Revenue by Manufacturers
3.2.1 Hepatic Encephalopathy (HE) Therapeutics Revenue by Manufacturers (2014-2019)
3.2.2 Hepatic Encephalopathy (HE) Therapeutics Revenue Share by Manufacturers (2014-2019)
3.2.3 Global Hepatic Encephalopathy (HE) Therapeutics Market Concentration Ratio (CR5 and HHI)
3.3 Hepatic Encephalopathy (HE) Therapeutics Price by Manufacturers
3.4 Key Manufacturers Hepatic Encephalopathy (HE) Therapeutics Plants/Factories Distribution and Area Served
3.5 Date of Key Manufacturers Enter into Hepatic Encephalopathy (HE) Therapeutics Market
3.6 Key Manufacturers Hepatic Encephalopathy (HE) Therapeutics Product Offered
3.7 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Sales and Revenue for Each Type
4.1.1 Lactulose Sales and Revenue (2014-2019)
4.1.2 Rifaximin Sales and Revenue (2014-2019)
4.1.3 Neomycin Sales and Revenue (2014-2019)
4.1.4 Probiotics Sales and Revenue (2014-2019)
4.1.5 Thiamine Sales and Revenue (2014-2019)
4.2 Global Hepatic Encephalopathy (HE) Therapeutics Sales Market Share by Type
4.3 Global Hepatic Encephalopathy (HE) Therapeutics Revenue Market Share by Type
4.4 Hepatic Encephalopathy (HE) Therapeutics Price by Type
5 Market Size by Application
5.1 Overview
5.2 Global Hepatic Encephalopathy (HE) Therapeutics Sales by Application
6 United States
6.1 United States Hepatic Encephalopathy (HE) Therapeutics Breakdown Data by Company
6.2 United States Hepatic Encephalopathy (HE) Therapeutics Breakdown Data by Type
6.3 United States Hepatic Encephalopathy (HE) Therapeutics Breakdown Data by Application
7 European Union
7.1 European Union Hepatic Encephalopathy (HE) Therapeutics Breakdown Data by Company
7.2 European Union Hepatic Encephalopathy (HE) Therapeutics Breakdown Data by Type
7.3 European Union Hepatic Encephalopathy (HE) Therapeutics Breakdown Data by Application
8 China
8.1 China Hepatic Encephalopathy (HE) Therapeutics Breakdown Data by Company
8.2 China Hepatic Encephalopathy (HE) Therapeutics Breakdown Data by Type
8.3 China Hepatic Encephalopathy (HE) Therapeutics Breakdown Data by Application
9 Rest of World
9.1 Rest of World Hepatic Encephalopathy (HE) Therapeutics Breakdown Data by Company
9.2 Rest of World Hepatic Encephalopathy (HE) Therapeutics Breakdown Data by Type
9.3 Rest of World Hepatic Encephalopathy (HE) Therapeutics Breakdown Data by Application
9.4 Rest of World Hepatic Encephalopathy (HE) Therapeutics Breakdown Data by Countries
9.4.1 Rest of World Hepatic Encephalopathy (HE) Therapeutics Sales by Countries
9.4.2 Rest of World Hepatic Encephalopathy (HE) Therapeutics Revenue by Countries
9.4.3 Japan
9.4.4 Korea
9.4.5 India
9.4.6 Southeast Asia
10 Company Profiles
10.1 ASKA Pharmaceutical
10.1.1 ASKA Pharmaceutical Company Details
10.1.2 Company Description and Business Overview
10.1.3 Sales, Revenue and Market Share of Hepatic Encephalopathy (HE) Therapeutics
10.1.4 Hepatic Encephalopathy (HE) Therapeutics Product Introduction
10.1.5 ASKA Pharmaceutical Recent Development
10.2 COSMO PHARMACEUTICALS
10.2.1 COSMO PHARMACEUTICALS Company Details
10.2.2 Company Description and Business Overview
10.2.3 Sales, Revenue and Market Share of Hepatic Encephalopathy (HE) Therapeutics
10.2.4 Hepatic Encephalopathy (HE) Therapeutics Product Introduction
10.2.5 COSMO PHARMACEUTICALS Recent Development
10.3 Mallinckrodt
10.3.1 Mallinckrodt Company Details
10.3.2 Company Description and Business Overview
10.3.3 Sales, Revenue and Market Share of Hepatic Encephalopathy (HE) Therapeutics
10.3.4 Hepatic Encephalopathy (HE) Therapeutics Product Introduction
10.3.5 Mallinckrodt Recent Development
10.4 Valeant
10.4.1 Valeant Company Details
10.4.2 Company Description and Business Overview
10.4.3 Sales, Revenue and Market Share of Hepatic Encephalopathy (HE) Therapeutics
10.4.4 Hepatic Encephalopathy (HE) Therapeutics Product Introduction
10.4.5 Valeant Recent Development
11 Value Chain and Sales Channels Analysis
11.1 Value Chain Analysis
11.2 Sales Channels Analysis
11.2.1 Hepatic Encephalopathy (HE) Therapeutics Sales Channels
11.2.2 Hepatic Encephalopathy (HE) Therapeutics Distributors
11.3 Hepatic Encephalopathy (HE) Therapeutics Customers
12 Market Forecast
12.1 Global Hepatic Encephalopathy (HE) Therapeutics Sales and Revenue Forecast 2019-2025
12.2 Global Hepatic Encephalopathy (HE) Therapeutics Sales Forecast by Type
12.3 Global Hepatic Encephalopathy (HE) Therapeutics Sales Forecast by Application
12.4 Hepatic Encephalopathy (HE) Therapeutics Forecast by Regions
12.4.1 Global Hepatic Encephalopathy (HE) Therapeutics Sales Forecast by Regions 2019-2025
12.4.2 Global Hepatic Encephalopathy (HE) Therapeutics Revenue Forecast by Regions 2019-2025
12.5 United States Market Forecast
12.6 European Union Market Forecast
12.7 China Market Forecast
12.8 Rest of World
12.8.1 Japan
12.8.2 Korea
12.8.3 India
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.1.1 Research Programs/Design
14.1.1.2 Market Size Estimation
14.1.1.3 Market Breakdown and Data Triangulation
14.1.2 Data Source
14.1.2.1 Secondary Sources
14.1.2.2 Primary Sources
14.2 Author Details
14.3 Disclaimer
